Injectable Polypeptide Hydrogel for Local Post-Surgical Tumor Drug Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for malignant tumors, particularly gliomas, brain metastases, bone tumors, and melanomas, face challenges such as incomplete surgical resection, high recurrence rates, and ineffective post-operative therapies, with systemic drug administration leading to low drug utilization at tumor sites and significant systemic toxicity.
Innovation Solution
A bionic hybrid injectable polypeptide hydrogel is prepared using ECM-derived Fmoc-DDIKVAV and Fmoc-FTKPRF peptides, which self-assemble into a drug reservoir that can be implanted in post-surgical cavities, providing controlled and stable drug release to kill residual tumor cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If systemic drug administration is used to treat residual tumor cells, then drug distribution is achieved throughout the body, but drug utilization at tumor sites is low and systemic toxicity is significant
Solution Approach 1:
The patent applies local quality by transitioning from systemic drug administration to localized hydrogel implantation at the tumor site. The hydrogel delivers drugs directly where needed (residual tumor cells in the cavity), concentrating the therapeutic effect locally while minimizing exposure to healthy tissues throughout the body, thereby resolving the contradiction between drug utilization and systemic toxicity
Solution Approach 2:
The hydrogel acts as an intermediary carrier that enables controlled local drug delivery. It serves as a bridge between the drug and the residual tumor cells, allowing sustained release of chemotherapy drugs directly at the tumor site while preventing systemic distribution, thus resolving the contradiction between achieving adequate drug utilization and avoiding systemic toxicity
2Reliability
If conventional chemotherapy is administered post-operatively, then treatment of residual tumor cells is attempted, but recurrence rates remain high due to ineffective therapy
Solution Approach 1:
The hydrogel provides continuous and sustained drug release over an extended period (weeks to months) directly at the tumor site, replacing the discontinuous intermittent dosing of conventional chemotherapy. This continuous local delivery ensures persistent therapeutic action against residual tumor cells, thereby improving treatment reliability and reducing recurrence rates
Solution Approach 2:
The hydrogel is implanted immediately after surgical resection, performing preliminary action by establishing a localized drug delivery system before residual tumor cells can proliferate. This timely local intervention ensures that chemotherapy drugs are delivered directly to the site of residual cells from the outset, enhancing treatment efficacy and preventing recurrence
3Quantity of substance
If complete surgical resection is performed on infiltrative tumors, then tumor burden is reduced, but recurrence occurs due to undetectable invasive foci in surrounding tissue
Solution Approach 1:
The hydrogel is implanted immediately after surgical resection as a preliminary protective measure, establishing a localized drug delivery system before residual tumor cells can proliferate. This timely local intervention targets microscopic invasive foci that may have been left behind during surgery, enhancing the reliability of complete resection by eliminating residual cells that standard surgery cannot remove
Solution Approach 2:
The hydrogel serves as an intermediary therapeutic layer between surgical resection and potential recurrence. It delivers chemotherapy drugs directly to the cavity where residual cells exist, acting as a bridge that eliminates microscopic disease without requiring more aggressive surgical intervention, thereby improving the reliability of complete tumor removal
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The hydrogel effectively targets residual tumor cells with minimal systemic toxicity, offering a simple and practical method for local drug delivery that enhances treatment efficacy and reduces side effects.
Implementation Method 1
dissolving Fmoc-DDIKVAV and Fmoc-FTKPRF peptides in a buffer solution to obtain a mixed solution I; adding NaOH solution to the mixed solution I to completely dissolve solid particles, obtaining a solution II; adjusting the solution II to neutral pH to initiate self-assembly (co-assembly), thereby obtaining the bionic hybrid injectable polypeptide hydrogel
Implementation Method 2
The drugs loaded in the hydrogel are slowly released at a stable and controlled rate and appropriate concentration within the post-surgical cavity
Data Source
AI summary
A method for preparing a bionic injectable polypeptide hydrogel is provided. The hydrogel is formed using a brain extracellular matrix laminin-derived peptide DDIKVAV modified with 9-fluorenylmethoxycarbonyl (Fmoc) (Fmoc-DDIKVAV) and an immunostimulatory peptide FTKPRF modified with Fmoc (Fmoc-FTKPRF) as hydrogel monomers. These monomers further utilize non-covalent bond forces such as hydrogen bonds, hydrophobic interactions, and x-x stacking to co-assemble into a hydrogel within a short time at 37° C. The bionic hybrid polypeptide hydrogel is injectable and can serve as a drug reservoir implanted into cavities formed after tumor surgery. The drugs loaded in the hydrogel are slowly released at a stable and controlled rate and appropriate concentration within the post-surgical cavity, thereby effectively killing residual tumor cells while avoiding the toxic side effects of systemic drug administration.